Mga Batayang Estadistika
| CIK | 1867096 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Xeris Biopharma Holdings, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of incorporation) (Comm |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40880 XERIS BIOP |
|
| August 7, 2025 |
Exhibit 99.1 XERIS BIOPHARMA REPORTS RECORD FINANCIAL RESULTS FOR THE SECOND QUARTER 2025 AND RAISES FULL YEAR REVENUE GUIDANCE Total revenue increased 49% YoY to $71.5 million; Recorlev® revenue grew 136% YoY Raises full-year 2025 total revenue guidance to $280-$290 million from previous range of $260-$275 million Provided long-term outlook at Analyst and Investor Day in June Hosts conference cal |
|
| June 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2025 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of incorporation) (Commis |
|
| June 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2025 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of incorporation) (Commis |
|
| June 3, 2025 |
exh991xeris-analystxdayx Investor and Analyst Day June 3, 2025 1 Exhibit 99.1 Copyright © 2021-2025 Xeris Pharmaceuticals, Inc. All rights reserved. Welcome and Agenda Allison Wey SVP, Investor Relations and Corporate Communications 2 Copyright © 2021-2025 Xeris Pharmaceuticals, Inc. All rights reserved. Important Disclosures Forward-Looking Statements and Other Information Any statements in prese |
|
| June 3, 2025 |
Exhibit 99.2 XERIS UNVEILS STRATEGY FOR LONG-TERM GROWTH AND VALUE CREATION AT 2025 ANALYST & INVESTOR DAY Company to discuss long-range financial outlook and strategic roadmap for rapid and sustainable growth CHICAGO, IL; June 3, 2025 – Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing inn |
|
| May 9, 2025 |
May 9, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Xeris Biopharma Holdings, Inc. Acceleration Request for Registration Statement on Form S-3 (File No. 333-285597) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Xeris Biopharma Holdin |
|
| May 8, 2025 |
Exhibit 99.1 XERIS BIOPHARMA REPORTS RECORD FIRST QUARTER 2025 FINANCIAL RESULTS Total revenue increased 48% YoY to over $60 million Recorlev® revenue grew 141% on YoY basis Tightens full-year total revenue 2025 guidance to $260 million to $275 million Announces upcoming Investor and Analyst Day on June 3rd in New York City Hosts conference call and webcast today at 8:30 a.m. ET CHICAGO, IL (BUSIN |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40880 XERIS BIO |
|
| May 8, 2025 |
1 ACTIVE/117159043.1 XERIS BIOPHARMA HOLDINGS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy of Xeris Biopharma Holdings, Inc. (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long- term basis, high-caliber directors who are not employees or officers of the Company or its |
|
| May 8, 2025 |
Consulting Agreement, dated April 1, 2025, by and between the Registrant and Ken Johnson CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the “Agreement”) made April 1, 2025, is entered into by Xeris Pharmaceuticals, Inc. |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of incorporation) (Commiss |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Defin |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2025 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of incorporation) (Comm |
|
| March 28, 2025 |
XERIS ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS Exhibit 99.1 XERIS ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS CHICAGO, IL; March 28, 2025 – Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced changes to its board of directors. Ricki Fairley has resigned from the board in |
|
| March 6, 2025 |
As filed with the Securities and Exchange Commission on March 6, 2025. As filed with the Securities and Exchange Commission on March 6, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 87-1082097 (State or other jurisdiction of incorporation or organization) ( |
|
| March 6, 2025 |
ex191-xerispolicyoninsid 2 XERIS BIOPHARMA HOLDINGS, INC. STATEMENT OF COMPANY POLICY ON INSIDER TRADING AND DISCLOSURE This memorandum sets forth the policy of Xeris Biopharma Holdings, Inc. and its subsidiaries (collectively, the “Company”) regarding trading in the Company’s securities as described below and the disclosure of information concerning the Company. This Insider Trading Policy (the “ |
|
| March 6, 2025 |
As filed with the Securities and Exchange Commission on March 6, 2025 As filed with the Securities and Exchange Commission on March 6, 2025 Registration No. |
|
| March 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40880 XERIS BIOPHARM |
|
| March 6, 2025 |
1 XERIS PHARMACEUTICALS, INC. 2018 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Xeris Pharmaceuticals, Inc. 2018 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Xeris Pharmaceuticals, Inc. (the “Company”) and its Subs |
|
| March 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2025 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of incorporation) (Commi |
|
| March 6, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Xeris Biopharma Holdings, Inc. |
|
| March 6, 2025 |
Subsidiaries of the Registrant Exhibit 21.1 XERIS BIOPHARMA HOLDINGS, INC. LIST OF SUBSIDIARIES Name Jurisdiction of Incorporation Xeris Pharmaceuticals, Inc. Delaware Xeris Pharmaceuticals Australia Pty Ltd Australia Strongbridge Biopharma Limited Ireland Strongbridge Dublin Limited Ireland Cortendo AB Sweden |
|
| March 6, 2025 |
Exhibit 4.7 XERIS BIOPHARMA HOLDINGS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Subordinated Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’ |
|
| March 6, 2025 |
1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (“Agreement”) is made by and among Xeris Biopharma Holdings, Inc. |
|
| March 6, 2025 |
Exhibit 99.1 XERIS BIOPHARMA DELIVERS RECORD FOURTH QUARTER AND FULL-YEAR 2024 RESULTS; AND ANNOUNCES 2025 GUIDANCE Achieved record quarterly and full-year total revenue of $60M and $203M, growing 35% and 24% versus prior year Recorlev® revenue more than doubled versus prior year and grew 28% in the fourth quarter sequentially Ended Q4 with over $71M in cash, generating $2M in cash in the fourth q |
|
| March 6, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Xeris Biopharma Holdings, Inc. |
|
| February 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of incorporation) (C |
|
| February 24, 2025 |
Exhibit 99.1 XERIS APPOINTS ANH NGUYEN, MD, MBA AS CHIEF MEDICAL OFFICER Kenneth Johnson, PharmD, SVP Global Development & Medical Affairs to retire CHICAGO, IL; February 24, 2025 – Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today a |
|
| January 10, 2025 |
Exhibit 99.1 XERIS EXPECTS TO EXCEED FULL-YEAR 2024 FINANCIAL GUIDANCE Full-year 2024 total revenue projected to be $203 million, exceeding previous guidance of $198-$202 million Year-end 2024 cash position expected to be over $71 million, generating positive cash flow in the fourth quarter Recorlev® net revenue Q4 2024 anticipated to increase by approximately $5 million or 28% sequentially 2024 f |
|
| January 10, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of incorporation) (Co |
|
| November 8, 2024 |
Exhibit 99.1 XERIS BIOPHARMA REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS Achieved record total revenue of $54.3M including record product revenue of $52.9M Product revenue increased 27% versus prior year and 14% over the prior quarter Ended Q3 with $69.4M in cash, cash equivalents and short-term investments Raises full-year guidance of total net revenue to $198M-$202M and tightens year-end cash t |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40880 XERIS |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2024 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of incorporation) (Co |
|
| November 8, 2024 |
1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED FIRST AMENDMENT TO AMENDED AND RESTATED PRODUCT SUPPLY AGREEMENT This First Amendment to Amended and Restated Product Supply Agreement (this “Amendment”) dated as of September 20, 2024 (the “Amendment Effective Date”) is entered into by and between Xeris Pharmaceuticals, Inc. |
|
| November 8, 2024 |
Xeris Biopharma Holdings, Inc. Non-Employee Director Compensation Policy 1 ACTIVE/117159043.1 XERIS BIOPHARMA HOLDINGS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy of Xeris Biopharma Holdings, Inc. (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long- term basis, high-caliber directors who are not employees or officers of the Company or its |
|
| November 8, 2024 |
1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED FIRST AMENDMENT TO STATEMENT OF WORK NO. |
|
| November 8, 2024 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED THIRD AMENDMENT TO API SUPPLY AGREEMENT This Third Amendment (“Third Amendment”) is entered into as of October 15, 2024 (the “Third Amendment Effective Date”), by and between Xeris Pharmaceuticals, Inc. |
|
| November 8, 2024 |
1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED SECOND AMENDMENT TO STATEMENT OF WORK NO. |
|
| August 8, 2024 |
strongbridgeregissupply CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED Manufacturing and Supply Agreement This Manufacturing and Supply Agreement (this “Agreement”) is entered into as of the 14th day of January, 2022 (the “Effective Date”), by and between Strongbridge Dublin Limited, a wholly- owned subsidiary of Strongbridge Biopharma Limited (f/k/a Strongbridge Biopharma plc), a company incorporated under the laws of Ireland having its registered office at Suite 206, Fitzwilliam Place, Dublin 2, D02 T292, Ireland (“Customer”), and Regis Technologies, Inc. |
|
| August 8, 2024 |
EX-FILING FEES 2 exhibit107filingfeetablees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Xeris Biopharma Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Pr |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of incorporation) (Comm |
|
| August 8, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 8, 2024 |
Exhibit 99.1 XERIS XERIS BIOPHARMA REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS Achieved revenue of $48.1M including record product revenue of $46.5M Total revenues increased 18% over the prior quarter and 26% over the same period prior year Ended Q2 with $77.6M in cash, cash equivalents and short-term investments Tightens full-year 2024 guidance: total net revenue to $190M-$200M and year-end cas |
|
| August 8, 2024 |
xeris-lonzacsaamendment1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED 1 AMENDMENT NO. |
|
| August 8, 2024 |
As filed with the Securities and Exchange Commission on August 8, 2024 As filed with the Securities and Exchange Commission on August 8, 2024 Registration No. |
|
| August 8, 2024 |
xeris-lonzacsa CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED 1 of 17 COMMERCIAL MANUFACTURING SERVICES AND SUPPLY AGREEMENT This Commercial Manufacturing Services and Supply Agreement (the "Agreement") is made and entered into as |
|
| August 6, 2024 |
1375 West Fulton Street, Suite 1300, Chicago IL 60607 August 6, 2024 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2024 (August 1, 2024) XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of inc |
|
| August 2, 2024 |
secondamendedandrestated 1 ACTIVE/112462414.1 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Second Amended and Restated Employment Agreement (“Agreement”) is made by and among Xeris Biopharma Holdings, Inc., a Delaware corporation (the “Parent”), Xeris Pharmaceuticals, Inc., a Delaware corporation and wholly-owned subsidiary of the Parent (the “Company”), and Kevin McCulloch (the “Executiv |
|
| July 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2024 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of incorporation) (Commis |
|
| July 8, 2024 |
Transition Agreement, dated as of July 7, 2024, by and between the Registrant and Paul R. Edick July 7, 2024 Paul R. Edick Re: Transition Agreement Dear Paul: This letter confirms our agreement regarding your transition from the role of Chief Executive Officer of Xeris Biopharma Holdings Inc., a Delaware corporation (the “Parent”), and Xeris Pharmaceuticals, Inc., a Delaware corporation and wholly owned subsidiary of the Parent (the “Company”) and your future services as a Senior Advisor. Th |
|
| July 8, 2024 |
SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Second Amended and Restated Employment Agreement (“Agreement”) is made as of July 7, 2024, by and among Xeris Biopharma Holdings, Inc. |
|
| July 8, 2024 |
Exhibit 99.1 XERIS BIOPHARMA ANNOUNCES CEO SUCCESSION PLAN John Shannon, President and Chief Operating Officer, to succeed Paul Edick as new CEO and Board Director Transition timing aligns with the solid financial position of the Company, including consistently strong growth from its commercial franchise, healthy cash position, and the track record of its leadership team Q2 ’24 total revenue is an |
|
| June 21, 2024 |
1375 West Fulton Street, Suite 1300, Chicago, IL 60607 June 21, 2024 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2024 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of incorporation) (Commis |
|
| June 5, 2024 |
First Amendment to Xeris Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan ex101xeris-amendmentno1t FIRST AMENDMENT TO THE XERIS PHARMACEUTICALS, INC. 2018 EMPLOYEE STOCK PURCHASE PLAN WHEREAS, Xeris Biopharma Holdings, Inc., a Delaware corporation incorporated under (the “Company”), maintains and operates the Xeris Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan (the “ESPP”), which was previously adopted by the board of directors and approved by the stockholders |
|
| May 9, 2024 |
Amendment to Strongbridge Biopharma plc 2017 Inducement Plan, dated February 28, 2024 a2-23x24xerisxamendmentt ACTIVE/126414441.2 AMENDMENT TO STRONGBRIDGE BIOPHARMA PLC 2017 INDUCEMENT PLAN A. The Strongbridge Biopharma plc 2017 Inducement Plan (the “Plan”) is hereby amended by deleting the first sentence of Section 4(a) and substituting therefore the following: “Subject to adjustment as described below, the Company Stock available for Awards under the Plan is 0 (the “Share Pool”) |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of incorporation) (Commiss |
|
| May 9, 2024 |
xerishayfin-arcreditagr ACTIVE/127969614 EXECUTION VERSION AMENDED AND RESTATED CREDIT AGREEMENT AND GUARANTY dated as of March 5, 2024 by and among XERIS PHARMACEUTICALS, INC. |
|
| May 9, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 9, 2024 |
Exhibit 99.1 XERIS BIOPHARMA REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND RECENT EVENTS Q1 2024 Total Revenue of $40.6M – up 22% over Q1 2023 Tightening full-year 2024 total revenue guidance to $175M-$200M Ended Q1 with $87.4M in cash, cash equivalents, and short-term investments, lowered borrowing rate of Hayfin debt by 2.05% Entered into a worldwide license agreement for XeriJect® formulatio |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Defin |
|
| March 6, 2024 |
Xeris Biopharma Holdings, Inc. Compensation Recovery Policy COMPENSATION RECOVERY POLICY Adopted as of November 8, 2023 Xeris Biopharma Holdings, Inc. |
|
| March 6, 2024 |
Subsidiaries of the Registrant Exhibit 21.1 XERIS BIOPHARMA HOLDINGS, INC. LIST OF SUBSIDIARIES Name Jurisdiction of Incorporation Xeris Pharmaceuticals, Inc. Delaware Xeris Pharmaceuticals Australia Pty Ltd Australia Strongbridge Biopharma Limited Ireland Strongbridge Dublin Limited Ireland Cortendo AB Sweden |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40880 XERIS BIOPHARM |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2024 (March 5, 2024) XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of incor |
|
| March 6, 2024 |
Exhibit 99.1 XERIS BIOPHARMA REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND RECENT EVENTS Achieved Total Revenue of over $44M in the fourth quarter - a 34% increase from same period prior year and generated approximately $164M for the full year 2023, a 49% increase versus prior year Ended 2023 with over $72M in cash, cash equivalents, and short-term investments achieving cash flow |
|
| March 6, 2024 |
As filed with the Securities and Exchange Commission on March 6, 2024 As filed with the Securities and Exchange Commission on March 6, 2024 Registration No. |
|
| March 6, 2024 |
Exhibit 99.2 XERIS REFINANCES ITS $150M SENIOR SECURED TERM LOAN FACILITY WITH HAYFIN CAPITAL Improves cost of capital Increases committed capital to a total facility size of $215M CHICAGO, IL; March 6, 2024 – Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across |
|
| March 6, 2024 |
Amendment to Xeris Pharmaceuticals, Inc. Inducement Equity Plan Exhibit 4.3 AMENDMENT TO XERIS PHARMACEUTICALS, INC. INDUCEMENT EQUITY PLAN A.The Xeris Pharmaceuticals, Inc. Inducement Equity Plan (the “Plan”) is hereby amended by deleting the first sentence of Section 3(a) and substituting therefore the following: “The maximum number of shares of Stock reserved and available for issuance under the Plan shall be 1,636,010 shares, subject to adjustment as provi |
|
| March 6, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Xeris Biopharma Holdings, Inc. |
|
| March 6, 2024 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED FIRST AMENDMENT TO THE STATEMENT OF WORK NO. |
|
| February 13, 2024 |
XERS / Xeris Biopharma Holdings, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Xeris Biopharma Holdings Inc Title of Class of Securities: Common Stock CUSIP Number: 98422E103 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1 |
|
| February 13, 2024 |
XERS / Xeris Biopharma Holdings, Inc. / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Xeris Biopharma Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 98422E103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| January 4, 2024 |
Exhibit 99.1 XERIS BIOPHARMA UPDATES ITS OUTLOOK FOR 2023 Company expects to be cashflow positive for the fourth quarter, report total revenue at the high end of its previous guidance of $160M-$165M, and end 2023 with over $72M in cash, cash equivalents, and short-term investments, exceeding its previous guidance of $65M-$70M Company to report Q4 and FY 2023 financial results on or about March 6, |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2024 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of incorporation) (Com |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of incorporation) (Co |
|
| November 9, 2023 |
exhibit101-xerisxconsent Execution Version CONSENT TO CREDIT AND GUARANTY AGREEMENT This CONSENT TO CREDIT AND GUARANTY AGREEMENT, dated as of September 26, 2023 (this “Consent”), is by and among XERIS PHARMACEUTICALS, INC. |
|
| November 9, 2023 |
Exhibit 99.1 XERIS BIOPHARMA REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS Achieved record revenue of $48.3M – a 27% increase from prior quarter, and a 63% increase from same period prior year Tightens full-year 2023 revenue guidance from $155M-$165M to $160M-$165M Ended Q3 with $66.0M in cash, cash equivalents and short-term investments and remains on track to achieve cash flow breakeven in the fo |
|
| November 9, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| October 16, 2023 |
Exhibit 99.1 XERIS BIOPHARMA RAISES FULL-YEAR FINANCIAL GUIDANCE AND REAFFIRMS CASH FLOW BREAKEVEN IN Q4 2023 Raises year-end cash, cash equivalents, and short-term investment guidance from $55M-$65M to $65M-$70M 2023 Cash Utilization expected to be $52M-$57M Tightens 2023 Total Revenue guidance from $145M-$165M to $155M-$165M Received $6M milestone payment for successfully formulating sub-cutaneo |
|
| October 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2023 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of incorporation) (Co |
|
| September 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2023 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of incorporation) ( |
|
| September 29, 2023 |
xeris2023indentureexecut Exhibit 4.1 Execution Version XERIS BIOPHARMA HOLDINGS, INC., as issuer, XERIS PHARMACEUTICALS, INC., as Guarantor, and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of September 29, 2023 8.00% Convertible Senior Notes due 2028 ii TABLE OF CONTENTS Article 1. DEFINITIONS; RULES OF CONSTRUCTION .................................................. |
|
| September 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2023 (September 26, 2023) XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdictio |
|
| September 27, 2023 |
xeris-exchangeagreementf Exhibit 10.1 Execution Version September 26, 2023 Xeris Biopharma Holdings, Inc. Xeris Pharmaceuticals, Inc. c/o Xeris Biopharma Holdings, Inc. 1375 West Fulton Street, Suite 1300 Chicago, IL 60607 Attention: General Counsel Re: Exchange for Xeris Pharmaceuticals, Inc.’s 5.00% Convertible Senior Notes due 2025 Ladies and Gentlemen: Pursuant to the terms of this exchange ag |
|
| September 27, 2023 |
Xeris Biopharma Announces Private Convertible Note Exchange Transactions Exhibit 99.1 Xeris Biopharma Announces Private Convertible Note Exchange Transactions CHICAGO, IL; September 27, 2023 – Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that on September 26, 2023, it and Xeris Pharmaceut |
|
| August 8, 2023 |
Exhibit 99.1 XERIS BIOPHARMA REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS Achieved record revenue of $38.0M – a 14% increase from prior quarter, and a 50% increase from same period prior year Ended Q2 with over $80M in cash, cash equivalents and short-term investments Tightens full-year 2023 guidance: total net revenue of $145M-$165M; cash utilization of $57M-$67M; 2023 year-end cash balance of $ |
|
| August 8, 2023 |
a5-22x23bachemqualityxa CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED Amendment 5 to the Quality Assurance Agreement This Amendment 5 (the “Amendment 5”) is made as of February 24, 2023 (the “Effective Date”) by and between Bachem AG, an entity organized under the laws of Switzerland, with its principal place of business at Hauptstrasse 144, CH-4416 Bubendorf, Switzerland (“Bachem”), and Xeris Pharmaceuticals, lnc. |
|
| August 8, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 8, 2023 |
xeris-waiversvbmattersr Execution Version 1 AMENDMENT NO. 3, WAIVER AND CONSENT TO CREDIT AND GUARANTY AGREEMENT This AMENDMENT NO. 3, WAIVER AND CONSENT TO CREDIT AND GUARANTY AGREEMENT, dated as of April 21, 2023 (this “Amendment”), is by and among XERIS PHARMACEUTICALS, INC., a Delaware corporation (the “Borrower”), and XERIS BIOPHARMA HOLDINGS, INC., a Delaware corporation (“Parent”), the Lend |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of incorporation) (Comm |
|
| June 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2023 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of incorporation) (Commi |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of incorporation) (Commis |
|
| May 9, 2023 |
a101finalamendmentno2toc Execution Version NY-2481782.4 AMENDMENT NO. 2 TO CREDIT AGREEMENT AND GUARANTY This AMENDMENT NO. 2 TO CREDIT AGREEMENT AND GUARANTY, dated as of January 19, 2023 (this “Amendment”), is by and among XERIS PHARMACEUTICALS, INC., a Delaware corporation (the “Borrower”), and XERIS BIOPHARMA HOLDINGS, INC., a Delaware corporation ( “Parent”), the Lenders party hereto, and HAY |
|
| May 9, 2023 |
a106redactedversion-xeri CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED Execution Version OMNIBUS ASSIGNMENT AND ASSUMPTION AGREEMENT AND AMENDMENT NO. |
|
| May 9, 2023 |
a103redactedproductsuppl 1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED AMENDED AND RESTATED PRODUCT SUPPLY AGREEMENT This AMENDED AND RESTATED PRODUCT SUPPLY AGREEMENT (the “Agreement”), effective as of January 30, 2023 (the “Effective Date”), is made by and between SHL Pharma, LLC, a private limited liability company existing under the laws of Florida, with offices at 588 Jim Moran Boulevard, Deerfield Beach, Florida 33442 (“SHL”), and Xeris Pharmaceuticals, Inc. |
|
| May 9, 2023 |
a104redacteddevicesow1 Statement of Work No. 1 - Device This Statement of Work No. 1 (this “SOW” or “Statement of Work”) is effective as of January 30, 2023 (the “SOW Effective Date”) between SHL Pharma, LLC, a company existing under the laws of Florida, with offices at 588 Jim Moran Boulevard, Deerfield Beach, Florida 33442 (“SHL”), and Xeris Pharmaceuticals, Inc., a corporation existing under th |
|
| May 9, 2023 |
Exhibit 99.1 XERIS BIOPHARMA REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS Achieved first quarter total revenue of $33.2M representing 50% growth compared to Q1 2022 Ended Q1 2023 with $95.1M in cash, cash equivalents, and short-term investments Affirms 2023 guidance: total revenue of $135M-$165M; cash utilization from operating activities of $57M-$77M; year-end cash, cash equivalents, and short-te |
|
| May 9, 2023 |
a105redactedproductsow2- Statement of Work No. 2 - Product This Statement of Work No. 2 (this “SOW” or “Statement of Work”) is effective as of January 30, 2023 (the “SOW Effective Date”) between SHL Pharma, LLC, a company existing under the laws of Florida, with offices at 588 Jim Moran Boulevard, Deerfield Beach, Florida 33442 (“SHL”), and Xeris Pharmaceuticals, Inc., a corporation existing under |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of incorporation) (Commiss |
|
| May 9, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 9, 2023 |
a102redacted-pyramidlabo Document No: Revision: Revision Date: Replaces: Page: MSA-XPI Amendment 4 01/16/23 00 1 of 6 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED AMENDMENT NO. |
|
| May 9, 2023 |
a107redactedversion-taro CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED Execution Version OMNIBUS AMENDMENT NO. |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 29, 2023 |
Xeris Biopharma Holdings, Inc. Non-Employee Director Compensation Policy xeris-nonxemployeedirect 1 ACTIVE/117159043.1 XERIS BIOPHARMA HOLDINGS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy of Xeris Biopharma Holdings, Inc. (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long- term basis, high-caliber directors who are not employees or office |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2023 (March 27, 2023) XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of inc |
|
| March 17, 2023 |
Letter from KPMG LLP to the Securities and Exchange Commission dated March 17, 2023 EX-16.1 2 auditorletter.htm EX-16.1 Exhibit 16.1 March 17, 2023 Securities and Exchange Commission Washington, D.C. 20549 Ladies and Gentlemen: We were previously principal accountants for Xeris Biopharma Holdings, Inc. and subsidiaries (the “Company”) and, under the date of March 8, 2023, we reported on the consolidated financial statements of the Company as of and for the years ended December 31 |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2023 (March 13, 2023) XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of inc |
|
| March 8, 2023 |
Exhibit 99.1 XERIS BIOPHARMA REPORTS FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS AND PROVIDES 2023 FINANCIAL GUIDANCE Achieved fourth quarter net product revenue of $32.5M representing 52% growth compared to Q4 2021 Achieved full-year net product revenue of $109.3M representing 38% annual growth compared to 2021 on a pro forma basis Ended 2022 with $122.0M in cash, cash equivalents, and sh |
|
| March 8, 2023 |
As filed with the Securities and Exchange Commission on March 8, 2023 As filed with the Securities and Exchange Commission on March 8, 2023 Registration No. |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2023 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of incorporation) (Commi |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40880 XERIS BIOPHARM |
|
| March 8, 2023 |
Subsidiaries of the Registrant Exhibit 21.1 XERIS BIOPHARMA HOLDINGS, INC. LIST OF SUBSIDIARIES Name Jurisdiction of Incorporation Xeris Pharmaceuticals, Inc. Delaware Xeris Pharmaceuticals Australia Pty Ltd Australia Strongbridge Biopharma Limited Ireland Strongbridge Dublin Limited Ireland Cortendo AB Sweden |
|
| March 8, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Xeris Biopharma Holdings, Inc. |
|
| March 8, 2023 |
Form of Lender Warrant issued December 28, 2016 in connection with a411formoflenderwarranti Company: STRONGBRIDGE BIOPHARMA PUBLIC LIMITED COMPANY, a public limited company incorporated under the laws of Ireland Number of Shares: Class of Share: Ordinary Shares of nominal value US$0. |
|
| February 14, 2023 |
XERS / Xeris Biopharma Holdings Inc / CAXTON CORP Passive Investment SC 13G/A 1 d994036113g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Xeris Biopharma Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 98422E103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check t |
|
| February 13, 2023 |
XERS / Xeris Biopharma Holdings Inc / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Xeris Biopharma Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 98422E103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 10, 2023 |
FMAO / Farmers & Merchants Bancorp Inc / BlackRock Inc. Passive Investment us98422e1038021023.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) XERIX BIOPHARMA HOLDINGS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 98422e103 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| January 20, 2023 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2023 (January 19, 2023) XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of |
|
| January 5, 2023 |
Exhibit 99.1 XERIS BIOPHARMA UPDATES ITS OUTLOOK FOR 2022 Company expects to end 2022 with over $120M in cash, cash equivalents, and short-term investments and at the top of its net product revenue guidance of $105M-$110M Company to report Q4 and FY 2022 financial results on or about March 8, 2023 CHICAGO, IL; January 5, 2023 – Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented bioph |
|
| January 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2023 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of incorporation) (Com |
|
| November 9, 2022 |
exh101amendedandrestated 4860-4932-6383\13 AMENDED AND RESTATED LEASE LANDLORD: FULTON OGDEN VENTURE, LLC, A Delaware limited liability company TENANT: XERIS PHARMACEUTICALS, INC. |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of incorporation) (Co |
|
| November 9, 2022 |
Exhibit 99.1 XERIS BIOPHARMA REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND RECENT EVENTS Achieved record net product revenue of $29.6M – a 17% increase from Q2 ’22, and a 31% increase from same period prior year on a pro forma basis; tightens full-year total net product revenue guidance to $105M-$110M Ended Q3 with $93.4M in cash, cash equivalents and short-term investments; raises 2022 year-en |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40880 XERIS |
|
| November 9, 2022 |
exh103redacted-pyramidla Document No: Revision: Revision Date: Replaces: Page: MSA-XPI Amendment 3 08/22/22 00 1 of 6 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED AMENDMENT NO. |
|
| November 9, 2022 |
exh102amendmentno1tocred Execution Version NY-2439688 AMENDMENT NO. 1 TO CREDIT AGREEMENT AND GUARANTY This AMENDMENT NO. 1 TO CREDIT AGREEMENT AND GUARANTY, dated as of September 29, 2022 (this “Amendment”), is by and among XERIS PHARMACEUTICALS, INC., a Delaware corporation (the “Borrower”), and XERIS BIOPHARMA HOLDINGS, INC., a Delaware corporation (“Parent”), the Lenders party hereto, and HAYF |
|
| October 20, 2022 |
Copyright ?2017-2022 Xeris Biopharma Holdings. All rights reserved. Xeris Biopharma (Nasdaq: XERS) A growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies Exhibit 99.2 Copyright ?2017-2022 Xeris Pharmaceuticals, Inc. All rights reserved. Topline Results of Phase 1 Study of Levothyroxine: PO v |
|
| October 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2022 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of incorporation) (Co |
|
| October 20, 2022 |
Exhibit 99.1 XERIS BIOPHARMA ANNOUNCES POSITIVE TOPLINE PHASE 1 CLINICAL DATA OF ITS INVESTIGATIONAL SUBCUTANEOUS (SC) LEVOTHYROXINE (XP-8121); HOSTS CONFERENCE CALL AND WEBCAST Data demonstrate proof-of-concept showing a once weekly subcutaneous injection of XP-8121 provides similar exposure at steady-state as daily oral Synthroid? Simulation model implies dose conversion factor of 4X XP-8121 in |
|
| October 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2022 (September 29, 2022) XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction o |
|
| August 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2022 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of incorporation) (Com |
|
| August 10, 2022 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED SECOND AMENDMENT TO API SUPPLY AGREEMENT This Second Amendment (?Second Amendment?) is entered into as of May 2, 2022 (the ?Second Amendment Effective Date?), by and between Xeris Pharmaceuticals, Inc. |
|
| August 10, 2022 |
Exhibit 99.1 XERIS BIOPHARMA REPORTS SECOND QUARTER FINANCIAL RESULTS AND UPCOMING EVENTS Achieved record net product revenue of $25.3M ? a 15% increase from Q1 ?22, and a 34% increase from same period prior year on a pro forma basis Ended Q2 with $111.6M in cash, cash equivalents and short-term investments Reaffirms full-year total net product revenue of $105M-$120M; $50M in synergies by year-end |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40880 XERIS BIOP |
|
| June 8, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of incorporation) (Commis |
|
| May 11, 2022 |
Exhibit 99.1 XERIS BIOPHARMA REPORTS FIRST QUARTER FINANCIAL RESULTS AND UPCOMING EVENTS Launched Recorlev® and Gvoke® Kit Achieved Q1 net product revenue of $21.9M - a 33% increase from same period prior year on a pro forma basis Ended Q1 with $132.1M in cash, cash equivalents and short-term investments Affirming 2022 guidance for combined net product revenues of $105M - $120M, $50M in synergies, |
|
| May 11, 2022 |
, 2022, by and between the Registrant and Jefferies LLC Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM May 11, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Xeris Biopharma Holdings, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s com |
|
| May 11, 2022 |
Up to $75,000,000 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-262404 PROSPECTUS SUPPLEMENT (To Prospectus dated February 7, 2022) Up to $75,000,000 Common Stock We have entered into an Open Market Sale AgreementSM, or the Sales Agreement, with Jefferies LLC, or Jefferies or the Agent, dated May 11, 2022, relating to our common stock, par value $0.0001 per share, offered by this prospectu |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40880 XERIS BIO |
|
| May 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of incorporation) (Commis |
|
| May 11, 2022 |
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5. |
|
| May 11, 2022 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (?Agreement?) is made by and among Xeris Biopharma Holdings, Inc. |
|
| May 11, 2022 |
CREDIT AGREEMENT AND GUARANTY dated as of March 8, 2022 by and among XERIS PHARMACEUTICALS, INC. |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6( |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| March 11, 2022 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED The common stock, par value $0.0001 per share (?Common Stock?) of Xeris Biopharma Holdings, Inc. (the ?Company,? ?we,? ?us,? and ?our?) is registered under Section 12 of the Securities Exchange Act of 1934, as amended. The following description sets forth |
|
| March 11, 2022 |
As filed with the Securities and Exchange Commission on March 11, 2022 As filed with the Securities and Exchange Commission on March 11, 2022 Registration No. |
|
| March 11, 2022 |
Subsidiaries of the Registrant Exhibit 21.1 XERIS BIOPHARMA HOLDINGS, INC. LIST OF SUBSIDIARIES Name Jurisdiction of Incorporation Xeris Pharmaceuticals, Inc. Delaware Xeris Pharmaceuticals Australia Pty Ltd Australia Strongbridge Biopharma Limited Ireland Strongbridge Dublin Limited Ireland Cortendo AB Sweden |
|
| March 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40880 XERIS BIOPHARM |
|
| March 11, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Xeris Biopharma Holdings, Inc. |
|
| March 10, 2022 |
Exhibit 99.2 XERIS ANNOUNCES $150M SENIOR SECURED TERM LOAN FACILITY WITH HAYFIN CAPITAL $100M drawn down at close; repayment of existing term loan; near-term access to an additional $50M Provides significant operating and financial flexibility Cash flow breakeven expected by year-end 2023 CHICAGO, IL; March 10, 2022 ? Xeris Biopharma Holdings, Inc. (?Xeris? or ?the Company?) (Nasdaq: XERS), a bio |
|
| March 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 (March 8, 2022) XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of inco |
|
| March 10, 2022 |
Exhibit 99.1 XERIS BIOPHARMA REPORTS FOURTH QUARTER AND FULL-YEAR 2021 FINANCIAL RESULTS AND RECENT EVENTS Acquisition and integration of Strongbridge Biopharma completed; $50M in synergies to be realized by year-end 2022 Recorlev? approved by FDA FY ?21 pro forma net product revenues of $79M ? a 56% increase from prior year Well-capitalized with cash, cash equivalents, and short-term investments |
|
| February 11, 2022 |
XERS / Xeris Biopharma Holdings Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| February 8, 2022 |
15,358,362 Shares Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-262403 PROSPECTUS 15,358,362 Shares Common Stock This prospectus relates to the possible resale, from time to time, by the selling stockholder identified in this prospectus of up to (i) 10,238,908 shares of our common stock, par value $0.0001 per share (the ?Common Stock?), initially issued in a private placement (the ?Private Placement?), purs |
|
| February 4, 2022 |
February 4, 2022 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| February 4, 2022 |
February 4, 2022 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| January 28, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2022 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of incorporation) (Co |
|
| January 28, 2022 |
Form of Specimen Common Stock Certificate Exhibit 4.1 THIS CERTIFIES THAT is the owner of CUSIP DATED COUNTERSIGNED AND REGISTERED: COMPUTERSHARE TRUST COMPANY, N.A. TRANSFER?AGENT AND?REGISTRAR, FULLY-PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF Xeris Biopharma Holdings, Inc. (hereinafter called the ?Company?), transferable on the books of the Company in person or by duly authorized attorney, upon surrender of this Certificate prope |
|
| January 28, 2022 |
As filed with the Securities and Exchange Commission on January 28, 2022. As filed with the Securities and Exchange Commission on January 28, 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 87-1082097 (State or other jurisdiction of incorporation or organization |
|
| January 28, 2022 |
Unaudited Pro Forma Condensed Combined Financial Information of Xeris Biopharma Holdings, Inc. Exhibit 99.2 Unaudited Pro Forma Condensed Combined Financial Information of Xeris Biopharma Holdings, Inc. The following unaudited pro forma condensed combined financial information of Xeris Biopharma Holdings, Inc. (the "Company") is presented to illustrate the estimated effects of the Acquisition (defined in Note 1) of Strongbridge Biopharma plc (?Strongbridge?) by Xeris Pharmaceuticals, Inc. ( |
|
| January 28, 2022 |
As filed with the Securities and Exchange Commission on January 28, 2022. As filed with the Securities and Exchange Commission on January 28, 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 87-1082097 (State or other jurisdiction of incorporation or organization |
|
| January 28, 2022 |
Exhibit 4.1 THIS CERTIFIES THAT is the owner of CUSIP DATED COUNTERSIGNED AND REGISTERED: COMPUTERSHARE TRUST COMPANY, N.A. TRANSFER?AGENT AND?REGISTRAR, FULLY-PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF Xeris Biopharma Holdings, Inc. (hereinafter called the ?Company?), transferable on the books of the Company in person or by duly authorized attorney, upon surrender of this Certificate prope |
|
| January 28, 2022 |
Exhibit 4.6 XERIS BIOPHARMA HOLDINGS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Subordinated Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee? |
|
| January 28, 2022 |
Exhibit 99.1 Consolidated Financial Statements STRONGBRIDGE BIOPHARMA plc September 30, 2021 and 2020 1 STRONGBRIDGE BIOPHARMA plc Consolidated Balance Sheets (In thousands, except share and per share data) (unaudited) September 30, December 31, 2021 2020 ASSETS Current assets: Cash and cash equivalents $ 55,270 $ 87,522 Accounts receivable 5,325 2,801 Inventory 1,173 1,103 Prepaid expenses and ot |
|
| January 18, 2022 |
Exhibit 99.1 XERIS BIOPHARMA PROVIDES BUSINESS UPDATE AND REAFFIRMS 2021 GUIDANCE Preliminary 2021 full-year pro forma net sales at high-end of $76-80 million guidance, representing approximately 55% growth from 2020 Year-end 2021 preliminary cash, cash equivalents, and investments of approximately $102 million 20+ million Medicaid lives in IL, TN, PA, OH, and CA have unrestricted access to Gvoke? |
|
| January 18, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2022 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of incorporation) (Co |
|
| January 14, 2022 |
US98422E1038 / Xeris Biopharma Holdings Inc / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Xeris Biopharma Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 98422E103 (CUSIP Number) January 7, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| January 5, 2022 |
US98422E1038 / Xeris Biopharma Holdings Inc / CAXTON CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 3, 2022 |
Exhibit 10.2 Execution Copy REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of January 2, 2022, between Xeris Biopharma Holdings, Inc., a Delaware corporation (the ?Company?), and the purchaser signatory hereto (the ?Purchaser?). This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between |
|
| January 3, 2022 |
XERIS BIOPHARMA ENTERS INTO AGREEMENT FOR $30 MILLION PRIVATE PLACEMENT Exhibit 99.1 XERIS BIOPHARMA ENTERS INTO AGREEMENT FOR $30 MILLION PRIVATE PLACEMENT CHICAGO, IL; January 3, 2022 ? Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) (?Xeris? or the ?Company?), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that on January 2, 2022, it entered into a |
|
| January 3, 2022 |
, 2022 (Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K (File No. Exhibit 10.1 Execution Copy SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of January 2, 2022, between Xeris Biopharma Holdings, Inc., a Delaware corporation (the ?Company?), and the purchaser identified on the signature page hereto (including its successors and assigns, the ?Purchaser?). WHEREAS, subject to the terms and conditions set forth in thi |
|
| January 3, 2022 |
EX-4.1 2 d221763dex41.htm EX-4.1 Exhibit 4.1 Execution Copy NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED |
|
| January 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2022 (January 2, 2022) XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of i |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40880 XERIS |
|
| November 10, 2021 |
Exhibit 99.1 XERIS BIOPHARMA REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND OTHER HIGHLIGHTS Acquisition of Strongbridge Biopharma closed October 5, 2021; integration complete Q3 pro forma net sales of $22.5M: Gvoke? and Keveyis? $11.0M and $11.5M, respectively Gvoke and Keveyis net sales grew 19% compared to Q2 2021 and combined are on track to achieve $76M to $80M full year 2021 net sales On t |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of incorporation) (C |
|
| October 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2021 (October 5, 2021) XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of i |
|
| October 5, 2021 |
Exhibit 2.2 CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of October 5, 2021 (this ?Agreement?), is entered into by and between Xeris Biopharma Holdings, Inc., a Delaware corporation (?Parent?), and Computershare Inc., a Delaware corporation (?Computershare?) and its affiliate Computershare Trust Company, N.A., a federally chartered trust company (together with |
|
| October 5, 2021 |
Exhibit 4.3 Execution Version SECOND SUPPLEMENTAL INDENTURE This SECOND SUPPLEMENTAL INDENTURE, dated as of October 5, 2021 (the ?Second Supplemental Indenture?), is entered into among Xeris Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), Xeris Biopharma Holdings, Inc., a Delaware corporation (?Parent?), and U.S. Bank National Association, as trustee (the ?Trustee?). WHEREAS, the Co |
|
| October 5, 2021 |
Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (?Agreement?) is made by and among Xeris Biopharma Holdings, Inc., a Delaware corporation (the ?Parent?), Xeris Pharmaceuticals, Inc., a Delaware corporation and wholly-owned subsidiary of the Parent (the ?Company?), and Paul R. Edick (the ?Executive?) and is effective as of the closing date of th |
|
| October 5, 2021 |
Exhibit 10.2 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (?Agreement?) is made by and among Xeris Biopharma Holdings, Inc., a Delaware corporation (the ?Parent?), Xeris Pharmaceuticals, Inc., a Delaware corporation and wholly-owned subsidiary of the Parent (the ?Company?), and John Shannon (the ?Executive?) and is effective as of the closing date of the |
|
| October 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2021 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 333-257642 87-1082097 (State or other jurisdiction of incorporation) (Co |
|
| October 5, 2021 |
As filed with the Securities and Exchange Commission on October 5, 2021 As filed with the Securities and Exchange Commission on October 5, 2021 Registration No. |
|
| October 5, 2021 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF XERIS BIOPHARMA HOLDINGS, INC. (the ?Corporation?) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an ?Annual Meeting?) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and plac |
|
| October 5, 2021 |
Exhibit 10.3 XERIS BIOPHARMA HOLDINGS, INC. FORM OF OFFICER INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?) is made as of October [], 2021 by and between Xeris Biopharma Holdings, Inc., a Delaware corporation (the ?Company?), and (?Indemnitee?). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to se |
|
| October 5, 2021 |
Exhibit 4.1 XERIS PHARMACEUTICALS, INC., Issuer AND U.S. BANK NATIONAL ASSOCIATION, Trustee INDENTURE Dated as of June 30, 2020 Senior Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securiti |
|
| October 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2021 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 333-257642 87-1082097 (State or other jurisdiction of incorporation) (Co |
|
| October 5, 2021 |
Exhibit 10.2 XERIS BIOPHARMA HOLDINGS, INC. FORM OF DIRECTOR INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?) is made as of October [], 2021 by and between Xeris Biopharma Holdings, Inc., a Delaware corporation, (the ?Company?), and [] (?Indemnitee?). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, |
|
| October 5, 2021 |
EX-10.3 4 d184152dex103.htm EX-10.3 Exhibit 10.3 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (“Agreement”) is made by and among Xeris Biopharma Holdings, Inc., a Delaware corporation (the “Parent”), Xeris Pharmaceuticals, Inc., a Delaware corporation and wholly-owned subsidiary of the Parent (the “Company”), and Steven Pieper (the “Executive”) and is ef |
|
| October 5, 2021 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF XERIS BIOPHARMA HOLDINGS, INC. Xeris Biopharma Holdings, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: 1. The name of the Corporation is Xeris Biopharma Holdings, Inc.. The date of the filing of its original Certificate of Incorporation with the Se |
|
| October 5, 2021 |
Exhibit 4.2 XERIS PHARMACEUTICALS, INC. and U.S. BANK NATIONAL ASSOCIATION as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of June 30, 2020 5.00% Convertible Senior Notes due 2025 TABLE OF CONTENTS Article 1. DEFINITIONS; RULES OF CONSTRUCTION 1 Section 1.01. Definitions 1 Section 1.02. Other Definitions 6 Section 1.03. Rules of Construction 8 Section 1.04. Interpretation; Scope of Supplemental I |
|
| October 5, 2021 |
Press Release, dated October 5, 2021. EXHIBIT 99.1 XERIS PHARMACEUTICALS COMPLETES ACQUISITION OF STRONGBRIDGE BIOPHARMA Xeris Pharmaceuticals, Inc. and Strongbridge Biopharma plc are now subsidiaries of Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) CHICAGO, IL, October 5, 2021 ? Xeris Pharmaceuticals, Inc. (?Xeris?), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-u |
|
| October 5, 2021 |
Exhibit 10.1 JOINDER AND SIXTH AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT THIS JOINDER AND SIXTH AMENDMENT to Amended and Restated Loan and Security Agreement (this ?Amendment?) is entered into as of October 5, 2021, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (?Oxfo |
|
| July 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2021 (July 29, 2021) XERIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38536 20-3352427 (State or other jurisdiction of incorpor |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2021 (July 28, 2021) XERIS PHARMACEUTICALS, INC. 3 (Exact name of registrant as specified in its charter) Delaware 001-38536 20-3352427 (State or other jurisdiction of incorp |
|
| July 29, 2021 |
XERIS PHARMACEUTICALS, INC. 180 N. LaSalle Street, Suite 1600 Chicago, Illinois 60601 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-257642 XERIS PHARMACEUTICALS, INC. 180 N. LaSalle Street, Suite 1600 Chicago, Illinois 60601 To our Stockholders: You are cordially invited to attend a special meeting of the stockholders of Xeris Pharmaceuticals, Inc. (?Xeris?) to be held on September 14, 2021 at 8:00 a.m. Central Time. The special meeting will be held in a v |
|
| July 28, 2021 |
July 28, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| July 28, 2021 |
Certificate of Incorporation of the Registrant Exhibit 3.1 CERTIFICATE OF INCORPORATION OF XERIS BIOPHARMA HOLDINGS, INC. ARTICLE I The name of this corporation is Xeris Biopharma Holdings, Inc. (the ?Corporation?). ARTICLE II The address of the Corporation?s registered office in the State of Delaware is 1209 Orange Street, in the City of Wilmington, County of New Castle, 19801, and its registered agent at such address is The Corporation Trust |
|
| July 28, 2021 |
Consent of MTS Securities, LLC Exhibit 99.4 Consent of MTS Securities, LLC July 28, 2021 Board of Directors Strongbridge Biopharma plc 900 Northbrook Drive, Suite 200 Trevose, Pennsylvania 19053 Members of the Board of Directors: We hereby consent to the inclusion of our opinion letter, dated May 23, 2021, to the Board of Directors of Strongbridge Biopharma plc (?Strongbridge?) as Annex F to, and reference to such opinion lette |
|
| July 28, 2021 |
As filed with the U.S. Securities and Exchange Commission on July 28, 2021 Table of Contents As filed with the U.S. Securities and Exchange Commission on July 28, 2021 Registration No. 333-257642 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 87-1082097 (State or ot |
|
| July 28, 2021 |
Form of Proxy Card for Strongbridge Exhibit 99.6 STRONGBRIDGE BIOPHARMA PLC FORM OF PROXY COURT MEETING OF THE SCHEME SHAREHOLDERS ON SEPTEMBER 8, 2021 AT 12:00 P.M. (EASTERN TIME IN THE U.S) (5:00 P.M. IRISH TIME) AT 900 NORTHBROOK DRIVE, SUITE 200, TREVOSE, PENNSYLVANIA 19053, UNITED STATES OF AMERICA This proxy is solicited by the Board of Directors The Irish High Court has fixed 5:00 p.m. (Eastern Time in the U.S), on July 27, 2 |
|
| July 28, 2021 |
Exhibit 99.5 Xeris Pharmaceuticals P.O. BOX 8016, CARY, NC 27512-9903 YOUR VOTE IS IMPORTANT! PLEASE VOTE BY: INTERNET Go To: www.proxypush.com/XERS ? Cast your vote online ? Have your Proxy Card ready ? Follow the simple instructions to record your vote PHONE Call 1-866-229-1034 ? Use any touch-tone telephone ? Have your Proxy Card ready ? Follow the simple recorded instructions MAIL ? Mark, sign |
|
| July 28, 2021 |
Exhibit 3.3 XERIS BIOPHARMA HOLDINGS, INC. BYLAWS Adopted May 20, 2021 ARTICLE I STOCKHOLDERS Section 1. Annual Meeting. An annual meeting of the stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, on such date, and at such time as the Board of Directors |
|
| July 28, 2021 |
Exhibit 99.2 CONSENT OF SVB LEERINK LLC We hereby consent to the use of our opinion letter dated May 23, 2021 to the Board of Directors of Xeris Pharmaceuticals, Inc., included as Annex E to the joint proxy statement/prospectus which forms a part of the Registration Statement on Form S-4 of Xeris Pharmaceuticals, Inc., to be filed on the date hereof, and to the references to such opinion in such j |
|
| July 2, 2021 |
Certificate of Incorporation of the Registrant Exhibit 3.1 CERTIFICATE OF INCORPORATION OF XERIS BIOPHARMA HOLDINGS, INC. ARTICLE I The name of this corporation is Xeris Biopharma Holdings, Inc. (the ?Corporation?). ARTICLE II The address of the Corporation?s registered office in the State of Delaware is 1209 Orange Street, in the City of Wilmington, County of New Castle, 19801, and its registered agent at such address is The Corporation Trust |
|
| July 2, 2021 |
Consent of MTS Securities, LLC Exhibit 99.4 Consent of MTS Securities, LLC July 2, 2021 Board of Directors Strongbridge Biopharma plc 900 Northbrook Drive, Suite 200 Trevose, Pennsylvania 19053 Members of the Board of Directors: We hereby consent to the inclusion of our opinion letter, dated May 23, 2021, to the Board of Directors of Strongbridge Biopharma plc (?Strongbridge?) as Annex F to, and reference to such opinion letter |
|
| July 2, 2021 |
Table of Contents As filed with the U.S. Securities and Exchange Commission on July 2, 2021 Registration No. 333-[?] UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 87-1082097 (State or other jurisdiction of inc |
|
| July 2, 2021 |
Exhibit 3.3 XERIS BIOPHARMA HOLDINGS, INC. BYLAWS Adopted May 20, 2021 ARTICLE I STOCKHOLDERS Section 1. Annual Meeting. An annual meeting of the stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, on such date, and at such time as the Board of Directors |
|
| July 2, 2021 |
Exhibit 99.2 CONSENT OF SVB LEERINK LLC We hereby consent to the use of our opinion letter dated May 23, 2021 to the Board of Directors of Xeris Pharmaceuticals, Inc., included as Annex E to the joint proxy statement/prospectus which forms a part of the Registration Statement on Form S-4 of Xeris Pharmaceuticals, Inc., to be filed on the date hereof, and to the references to such opinion in such j |
